Contents

Preface ........................................ v
Contributors .................................... xi
1. In Vitro Methods of Evaluating Antithrombotics and Thrombolytics ....... 1
   Shaker A. Mousa
2. In Vivo Models for the Evaluation of Antithrombotics and Thrombolytics ... 29
   Shaker A. Mousa
3. Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond .... 109
   Shaker A. Mousa
4. Laboratory Methods and Management of Patients with Heparin-Induced
   Thrombocytopenia .................................. 133
   Margaret Prechel, Walter P. Jeske, and Jeanine M. Walenga
5. Novel Anticoagulant Therapy: Principle and Practice ......................... 157
   Shaker A. Mousa
6. Oral Direct Factor Xa Inhibitors, with Special Emphasis on Rivaroxaban .... 181
   Shaker A. Mousa
7. Antiplatelet Therapies: Drug Interactions in the Management
   of Vascular Disorders ................................ 203
   Shaker A. Mousa
8. Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist ............... 221
   Shaker A. Mousa, Walter P. Jeske, and Jawed Fareed
9. Antithrombotic Effects of Naturally Derived Products on Coagulation
   and Platelet Function ................................... 229
   Shaker A. Mousa
10. Assessment of Anti-Metastatic Effects of Anticoagulant and Antiplatelet
   Agents Using Animal Models of Experimental Lung Metastasis ............. 241
   Ali Amirkhosravi, Shaker A. Mousa, Mildred Amaya, Todd Meyer, 
   Monica Davila, Theresa Robson, and John L. Francis
11. Adhesion Molecules: Potential Therapeutic and Diagnostic Implications .... 261
    Shaker A. Mousa
12. Pharmacogenomics in Thrombosis ..................................... 277
    Shaker A. Mousa
13. Diagnosis and Management of Sickle Cell Disorders .......................... 291
    Shaker A. Mousa and Mohamad H. Qari

Subject Index ..................................... 309
Anticoagulants, Antiplatelets, and Thrombolytics
MOUSA, S. (Ed.)
2010, XII, 316 p., Hardcover
ISBN: 978-1-60761-802-7
A product of Humana Press